Jennifer Knight, MD, MS, FACLP

Associate Professor, Psychiatry and Behavioral Medicine and Microbiology & Immunology

Locations

Psychiatry and Behavioral Medicine

Contact Information

Learn more about the Knight Biobehavioral Oncology Laboratory

Biography

Dr. Knight completed her undergraduate training at the University of Wisconsin-Madison and her medical training at the Medical College of Wisconsin. She completed her residency training in a combined Internal Medicine and Psychiatry program at Rush University in Chicago, and is double board certified in both specialties. She also completed a post-doctoral research fellowship in psychoneuroimmunology at the University of Rochester Medical Center.

Research Interests

Dr. Knight’s research interests involve investigating the physiologic and immunologic effects that account for the relationship between psychosocial factors and clinical outcomes in hematopoietic stem cell transplant recipients. Clinically, she is the Medical Director of the Psycho-Oncology Program at Froedtert and MCW and specializes in general and psycho-oncology psychosomatic medicine consultation. She sees patients at the MCW Cancer Center and at Froedtert Hospital. She is on faculty at the Neuroscience Research Center and is also a Clinical Member of the MCW Cancer Center in the Transplantation Biology and Immunotherapy Research Program.

Examining the role of social relationships on health and health behaviors in African American men with prostate cancer: a qualitative analysis.

(Awoyinka I, Tovar M, Young S, Beyer K, Kwarteng J, Knight J, Stolley M.) Support Care Cancer. 2024 Feb 21;32(3):178 PMID: 38381216 SCOPUS ID: 2-s2.0-85185668818 02/21/2024
Experiences of racial discrimination and adverse gene expression among black individuals in a level 1 trauma center sample.

(Bird CM, Kate Webb E, Cole SW, Tomas CW, Knight JM, Timmer-Murillo SC, Larson CL, deRoon-Cassini TA, Torres L.) Brain Behav Immun. 2024 Feb;116:229-236 PMID: 38070623 PMCID: PMC10872243 SCOPUS ID: 2-s2.0-85180086979 12/10/2023
Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis.

(Taylor MR, Cole SW, Strom J, Brazauskas R, Baker KS, Phelan R, Buchbinder D, Hamilton B, Schoemans H, Shaw BE, Sharma A, Bhatt NS, Badawy SM, Winestone LE, Preussler JM, Mayo S, Jamani K, Nishihori T, Lee MA, Knight JM.) Blood Adv. 2023 Nov 28;7(22):6830-6838 PMID: 37773924 PMCID: PMC10679811 SCOPUS ID: 2-s2.0-85178332888 09/29/2023
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis.

(Blue BJ, Brazauskas R, Chen K, Patel J, Zeidan AM, Steinberg A, Ballen K, Kwok J, Rotz SJ, Perez MAD, Kelkar AH, Ganguly S, Wingard JR, Lad D, Sharma A, Badawy SM, Lazarus HM, Hashem H, Szwajcer D, Knight JM, Bhatt NS, Page K, Beattie S, Arai Y, Liu H, Arnold SD, Freytes CO, Abid MB, Beitinjaneh A, Farhadfar N, Wirk B, Winestone LE, Agrawal V, Preussler JM, Seo S, Hashmi S, Lehmann L, Wood WA, Rangarajan HG, Saber W, Majhail NS.) Transplant Cell Ther. 2023 Nov;29(11):709.e1-709.e11 PMID: 37482244 SCOPUS ID: 2-s2.0-85173143416 07/24/2023
A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy.

(Kleman A, Singavi A, Pommert L, Mathison AJ, Hari P, Dhakal B, Mohan M, Janz S, Knight JM, Shah MV, Schinke C, Burns R, Steinhardt GF, Rao S, Carlson K.) Blood Adv. 2023 Sep 26;7(18):5549-5553 PMID: 36724511 PMCID: PMC10514068 SCOPUS ID: 2-s2.0-85164933174 02/02/2023
Inflammatory cytokines and depression symptoms following hematopoietic cell transplantation.

(Nelson AM, Erdmann AA, Coe CL, Juckett MB, Morris K, Knight JM, Hematti P, Costanzo ES.) Brain Behav Immun. 2023 Aug;112:11-17 PMID: 37236325 PMCID: PMC10524437 SCOPUS ID: 2-s2.0-85160562513 05/27/2023
Mobile health (mHealth) interventions in prostate cancer survivorship: a scoping review.

(Ogunsanya ME, Sifat M, Bamidele OO, Ezenwankwo EF, Clifton S, Ton C, Knight JM, Odedina FT, Greer JA, Dwyer K, Kendzor DE.) J Cancer Surviv. 2023 Jun;17(3):557-568 PMID: 36627464 SCOPUS ID: 2-s2.0-85145983150 01/11/2023
Prevalence of Sleep Aid Medication Use in Patients Receiving a Hematopoietic Cell Transplant on an Inpatient Unit.

(Cusatis R, Ibrahim A, Knight JM, D'Souza A, Shaw BE.) Hematol Oncol Stem Cell Ther. 2023 May 23;16(4):366-369 PMID: 37363976 SCOPUS ID: 2-s2.0-85163346266 06/26/2023
Fit for Duty: Lessons Learned from Outpatient and Homebound Hematopoietic Cell Transplantation to Prepare Family Caregivers for Home-Based Care.

(Applebaum AJ, Sannes T, Mitchell HR, McAndrew NS, Wiener L, Knight JM, Nelson AJ, Gray TF, Fank PM, Lahijani SC, Pozo-Kaderman C, Rueda-Lara M, Miran DM, Landau H, Amonoo HL.) Transplant Cell Ther. 2023 Mar;29(3):143-150 PMID: 36572386 PMCID: PMC9780643 SCOPUS ID: 2-s2.0-85146470226 12/27/2022
Abrupt onset of severe parkinsonism in a patient with metastatic gastrointestinal stromal tumor receiving treatment with avapritinib: A case report.

(Drom C, Schenheit K, Matzke M, Obeidat AZ, Molinaro J, Charlson J, Knight JM.) Brain Behav Immun Health. 2023 Feb;27:100570 PMID: 36578920 PMCID: PMC9791578 12/30/2022
Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism.

(Satilmis H, Verheye E, Vlummens P, Oudaert I, Vandewalle N, Fan R, Knight JM, De Beule N, Ates G, Massie A, Moreaux J, Maes A, De Bruyne E, Vanderkerken K, Menu E, Sloan EK, De Veirman K.) J Pathol. 2023 Jan;259(1):69-80 PMID: 36245401 PMCID: PMC10953387 SCOPUS ID: 2-s2.0-85143222266 10/18/2022
Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions.

(Taylor MR, Steineck A, Lahijani S, Hall AG, Jim HSL, Phelan R, Knight JM.) Transplant Cell Ther. 2023 Jan;29(1):19-26 PMID: 36208728 SCOPUS ID: 2-s2.0-85143519815 10/09/2022